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Using a syringe-like device, Shigella delivers an array of virulence factors into host cells to facilitate bacterial
colonization and disable the host’s innate immune defense. In this issue of Cell Host & Microbe, Konradt and
colleagues (Konradt et al., 2011) show that Shigella also subverts adaptive immunity by targeting T cells
through a mechanism involving PIP2 breakdown.Pathogens have evolved multiple, often
redundant and overlapping mechanisms
to evade the cellular and humoral innate
immune defenses that the host deploys
upon sensing infection. For bacterial
pathogens, these mechanisms include
inhibition of phagocytosis by capsular
polysaccharide, recruitment of comple-
ment regulators to the bacterial surface,
and paralysis of phagocytes by secreted
or intracellularly delivered toxins. Less
well documented is the ability of bacterial
pathogens to prevent the generation of
an adaptive immune response or evade
the specific adaptive immune defenses
once these have developed. In the
last few years, it has been shown that
toxins from diverse bacteria such as
Helicobacter pylori, Bordetella pertussis,
and Bacillus anthracis are capable of
entering CD4+ T cells and incapacitating
them through different molecular mecha-
nisms (Baldari et al., 2005; Rossi Paccani
et al., 2008; Tournier et al., 2009). As
a result of these attacks, the generation
of effector helper T cells is impaired, re-
sulting in the failure of T cells to potentiate
the bactericidal activity of phagocytes
and to provide help to antigen-specific
B cells to develop into high-affinity anti-
body-producing plasma cells.
Shigella, the causative agent of bacil-
lary dysentery, very effectively evades
the adaptive immune response. In fact,
a protective immune response is only
observed after multiple infections and is
relatively short-lived. This is in part ex-
plained by the bacterium’s ability to
invade epithelial cells and to spread
directly from cell to cell, thus avoiding
immune detection. In addition, Shigella
downregulates chemokine expression in
infected epithelial cells, resulting in
reduced recruitment of dendritic cells(Phalipon and Sansonetti, 2007). Konradt
and collegues (Konradt et al., 2011) now
describe another mechanism of adaptive
immune repression by Shigella that
involves a toxin-mediated attack on
CD4+ T cells. The difference with Shigella
is that the toxin involved is not a secreted
soluble toxin but an effector protein that is
injected directly into the cytoplasm of the
T cell through a type III secretion system
(TTSS), a syringe-like structure that
permits the delivery of several effector
proteins directly from the bacterial cyto-
plasm to the target cell cytoplasm.
The paper describes several interesting
findings. Shigella is shown to invade
activated but not quiescent CD4+ T cells.
The reason for this selectivity is not
known, although the authors hypothesize
a potential role of molecules upregulated
during T cell activation, such as CD44
or a5b1 integrins. Invasion is dependent
on a functional TTSS. The Shigella TTSS
is a major virulence factor that is neces-
sary for epithelial cell invasion and in-
duction of inflammation. In addition,
Shigella uses this system to inject effector
proteins into phagocytes, resulting in
actin disorganization, suppression of
gene transcription, and ultimately cell
death (Ashida et al., 2011). However, cell
invasion is not necessary for the effect
on T cells, as it is shown that the TTSS
on the surface of the bacteria can engage
the plasma membrane of the cell from the
outside to deliver the effector proteins to
the cytoplasm immediately upon contact
with the cell. The end result is that the
T cells become refractory to chemokine-
dependent migration. Chemotaxis is
crucially required for CD4+ T cells
which have differentiated to effectors in
secondary lymphoid organs to reach their
sites of action (the T:B cell zone inCell Host & Microblymphoid tissues to provide help to acti-
vated B cells, the infected tissue to
provide help to phagocytes). Hence, by
impairing chemotaxis, Shigella effectively
suppresses the adaptive immune
response.
Using Shigella mutants lacking indi-
vidual TTSS effector proteins, IpgD, a
phosphatidylinositol 4-phosphatase that
hydrolyses phosphatidylinositol 4,5-bi-
phosphate (PIP2), was identified as being
necessary and sufficient to impair the
chemokine-induced migration of T cells.
Interestingly, IpgD was not necessary for
cell invasion; however, on injection, IpgD
was shown to rapidly deplete the plasma
membrane pool of PIP2, resulting in
reduced phosphorylation and inactivation
of ezrin, a member of the ezrin, radixin,
and moesin (ERM) protein family (see
Figure 1). These proteins connect cortical
F actin to the plasma membrane, thereby
contributing to the reorganization of actin
cytoskeleton that is necessary for cell
polarization and migration (Fehon et al.,
2010). Hence, by modulating the levels
of PIP2 through IpgD,Shigella has evolved
an effective mechanism to target the actin
cytoskeleton. Interestingly, other Shigella
TTSS effectors also attack the actin cyto-
skeleton, and remodeling of the actin
cytoskeleton is necessary for invasion of
epithelial cells (Ogawa et al., 2008). It is
intriguing that these effectors do not
seem to have any effect on T cell
chemotaxis.
Inhibition of T cell chemotaxis appears
to be a winning strategy to impair the
development or function of helper
T cells, as witnessed by its widespread
use by both bacterial (e.g., B. pertussis,
B. anthracis) and viral (e.g., HIV-1, HCV)
pathogens. Interestingly, modulation of
PIP2 is emerging as a common target ofe 9, April 21, 2011 ª2011 Elsevier Inc. 253
Figure 1. Impairment of T Cell Chemotaxis by Shigella
Schematic representation of the mechanism by which Shigella IpgD impairs
T cell migration. Shigella injects the lipid phophatase IpgD into the cytosol of
activated CD4+ T cells, causing a reduction in the cortical pool of PIP2 and
inactivation of the membrane-cytoskeleton linker ezrin, which results in defec-
tive chemotaxis.
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pathogens (e.g., Salmonella
SopB, HIV-1 Tat), and this
report by Konradt et al.
(2011) further underlines this
point, providing evidence
that the response to the
depletion in PIP2 is mediated
by inactivation of ERM
proteins.
Of note, the activity of PIP2
is not limited to promoting the
reorganization of the actin
cytoskeleton (Parry et al.,
2007). PIP2 regulates a
number of cellular processes
by assisting the recruitment
and stabilization to the cyto-
solic face of the plasma
membrane of a number of
signaling mediators contain-
ing pleckstrin homology (PH)
domains, a central one being
the kinase Akt/PKB, which isessential for survival signaling and also
promotes the polarization of Th1 cells. It
may therefore be expected that, when
injected into the cytosol of activated
T cells, IpgD may have pleiotropic func-
tions beyond F actin remodeling and
chemotaxis.
With the identification of T cells as
targets of Shigella, Konradt et al. (2011)
not only provide a convincing explanation
as to why adaptive immunity is short lived
in the context of Shigella infection but also
open a new area of investigation. The
TTSS has been amply documented as
a powerful device to deliver a variety of
effectors to the cytosol of the host cell,
and IpgD might represent only the tip of
the iceberg. It is conceivable that
other effectors are coinjected with IpgD
into T cells. These include GEF mimicks,
a protein tyrosine kinase, a phosphothreo-
nine lyase, and ubiquitin ligases254 Cell Host & Microbe 9, April 21, 2011 ª2(Schroeder and Hilbi, 2008), which may
subvert the signaling pathways control-
ling important cellular processes.
On a more general note, the studies of
the interactions of bacterial pathogens
with the host immune system have been
largely focused on innate immunity or, at
most, on the link between innate and
adaptive immunity. Adaptive immunity is
finally emerging as a central target of the
immune evasion strategies evolved by
bacteria. In the case of Shigella, the
bacterium can cross the intestinal epithe-
lium via M cells localized in the mucosa-
associated lymphoid tissue, where it can
encounter naive T cells. Furthermore,
after disrupting the epithelial barrier,
Shigella can reach the lamina propria,
where it can encounter activated T cells,
as directly shown in the Konradt et al.
(2011) report, where invasion of T cells
in vivo after crossing the epithelial011 Elsevier Inc.barrier is documented using
a rabbit ileal loop ligation
model. Hence, to achieve
a comprehensive under-
standing of how pathogens
suppress or subvert the
immune response, adaptive
immune cells must be put
into the picture.ACKNOWLEDGMENTS
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